

RISANKIZUMAB

BRAND NAME	SKYRIZI
DRUG CLASS	Immunosuppressant, cytokine modulator, monoclonal antibody (humanised)
AVAILABILITY	Prefilled syringe contains 75 mg/0.83 mL of risankizumab. Also contains sodium succinate hexahydrate, succinic acid, sorbitol and polysorbate-20. ¹ Contains less than 1 mmol of sodium. ¹
pH	No information
PREPARATION	Allow to reach room temperature before use. ¹
STABILITY	Store at 2 to 8 °C. Do not freeze. Protect from light. ¹
ADMINISTRATON	
IM injection	Not recommended
SUBCUT injection	Inject into the thigh, abdomen or upper arm. Suitable for self-administration after appropriate patient education. ¹ For a 150 mg dose give two injections of 75 mg each at least 3 cm apart. ²
IV injection	Not recommended
IV infusion	Not recommended
COMPATIBILITY	Do not mix with other medicines
INCOMPATIBILITY	No information

REFERENCES

1. Product information. Available from www.tga.gov.au. Accessed 14/07/2020.
2. Consumer medicine information. Available from www.tga.gov.au. Accessed 14/07/2020.